Jeffrey Allen is an Author at insauga. He specializes in topics related to medicine and healthcare, with a focus on medical specialties and diagnostics. His work has been featured in insauga, NeurologyLive, and GLG.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Milton, Canada (Local)
Not enough data
Not enough data
Jeffrey Allen's coverage focuses on local news in the Milton, Ontario area, with an emphasis on government announcements and community events. He covers a wide range of topics including healthcare, education, sports, real estate and community events. If you are reaching out to Jeffrey Allen for coverage or collaboration opportunities, consider pitching local stories related to these topics. For example, updates on local healthcare initiatives or educational developments would likely align well with his coverage focus. Additionally, highlighting community-oriented events and their impact could also resonate with his audience.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Suraj Muley, Thomas H. Brannagan, Joshua Alpers, Jeffrey Allen
Real-world CIDP data show IVIG slows disability progression and may ease pain, with insights on study limits and patient outcomes.
By: Jeffrey Allen, Joshua Alpers, Suraj Muley, Thomas H. Brannagan
Experts discuss tailoring IVIG for CIDP—optimizing dose and intervals, monitoring relapse risk, and overcoming access and tolerability barriers.
By: Suraj Muley, Jeffrey Allen, Thomas H. Brannagan, Joshua Alpers
Explore subcutaneous immunoglobulin for CIDP: HYQVIA and HYZENTRA data, who benefits most, and how it compares with IVIG side effects.
By: Joshua Alpers, Thomas H. Brannagan, Jeffrey Allen, Suraj Muley
FcRn inhibitors emerge for CIDP relapse prevention, yet biomarker gaps and careful transitions from IVIG shape who benefits.
By: Karissa Gable, Jeffrey Allen
For clinicians treating chronic inflammatory demyelinating polyneuropathy, numerical improvements on disability scales ultimately matter only if they translate into better function for patients.
As new therapies enter clinical practice, the questions clinicians ask often shift from whether a treatment works to how it can be used most effectively in the patients they see every day.
Body text: The treatment landscape for chronic inflammatory demyelinating polyneuropathy has changed considerably over the past several years, with targeted therapies expanding the options available to clinicians beyond traditional immunomodulatory approaches. As these therapies become integrated into routine practice, the focus is increasingly turning toward optimizing treatment selection and defining long-term therapeutic goals for individual patients.
